Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Osteopore Ltd. ( (AU:OSX) ) has issued an update.
Osteopore Limited, in collaboration with Queensland Children’s Hospital, has initiated a clinical trial to treat temporal hollowing in children post-cranial vault remodelling surgery for craniosynostosis. This trial, which employs a 3D-printed, patient-specific polycaprolactone-tricalcium phosphate onlay scaffold, aims to assess its feasibility in restoring frontotemporal contour, potentially offering a less invasive alternative to current methods. The study has received ethical clearance and is supported by Maddox’s Helping Hand Foundation, highlighting its potential impact on improving surgical outcomes for young patients.
More about Osteopore Ltd.
Osteopore Limited is an Australian-Singaporean regenerative medicine company recognized globally for its expertise in 3D-printed biomimetic and bioresorbable implants.
Average Trading Volume: 2,803,677
Technical Sentiment Signal: Sell
Current Market Cap: A$2.6M
Find detailed analytics on OSX stock on TipRanks’ Stock Analysis page.